Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Plasmodium falciparum Endoplasmic Reticulum (ER) protein folding and trafficking machinery is a complex network of chaperones and transporters essential for the parasite's survival and virulence (Külzer et al., 2012, PMID: 22438784). Key components include the Hsp70-family chaperone PfBiP and PfHsp90, which ensure correct protein folding, and the Sec61 translocon, which facilitates protein entry into the ER (Heiber et al., 2013, PMID: 23413034). This machinery is particularly vital for the export of hundreds of effector proteins into the host erythrocyte, a process necessary for host cell remodeling and immune evasion (Elsworth et al., 2014, PMID: 25043010). Disruption of these processes by inhibitors like 17-AAG or Brefeldin A triggers severe ER stress and the Unfolded Protein Response (UPR), leading to parasite growth arrest (Chaubey et al., 2014, PMID: 24634458). Because the parasite undergoes rapid multiplication and extensive protein synthesis during its intraerythrocytic cycle, it is highly sensitive to disruptions in ER proteostasis (Bridgford et al., 2018, PMID: 30104376). Targeting this machinery induces the accumulation of misfolded proteins, which is lethal to the parasite across multiple life stages (Promeneur et al., 2007, PMID: 17502371). Despite its potential as a drug target, the high structural similarity between Plasmodium and human ER chaperones poses a significant risk of host toxicity (Banumathy et al., 2003, PMID: 12804512).
Inhibition of molecular chaperones (e.g., Hsp70, Hsp90) or translocons (e.g., Sec61) to disrupt protein folding and transport, leading to lethal ER stress and proteotoxicity.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum Endoplasmic Reticulum Protein Folding and Trafficking Machinery.